Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFNγ-IRF1-SREBF2 Axis

Area of Science:

• Cancer immunology
• Tumor metabolism
• Immunotherapy

Background:

• Tumor cells utilize metabolic pathways to evade immune responses and resist immunotherapy.
• The impact of immunotherapy on tumor cell metabolism is not fully understood.

Purpose of the Study:

• To investigate how anti-PD-1 immunotherapy influences tumor cell metabolism.
• To elucidate the molecular mechanisms by which immunotherapy affects cholesterol biosynthesis.
• To explore the therapeutic potential of targeting tumor cholesterol metabolism in conjunction with immunotherapy.

Main Methods:

• Treatment of cancer cells with anti-PD-1 antibodies.
• Analysis of cytokine profiles, specifically interferon-gamma (IFN-γ).
• Investigation of gene expression related to cholesterol synthesis, including IRF1 and SREBF2.
• Assessment of tumor growth and drug sensitivity (statins) in response to treatment.

Main Results:

• Anti-PD-1 treatment induced interferon-gamma (IFN-γ) production.
• IFN-γ suppressed the expression of sterol regulatory element-binding protein 2 (SREBF2), a key regulator of cholesterol synthesis.
• Reduced cholesterol levels in tumor cells led to inhibited tumor growth.
• Tumor cells became more sensitive to statins, drugs that lower cholesterol.

Conclusions:

• Interferon-gamma (IFN-γ)-mediated suppression of cholesterol biosynthesis is a significant antitumor mechanism of anti-PD-1 immunotherapy.
• Targeting tumor cholesterol metabolism represents a promising strategy to enhance immunotherapy efficacy.